B-Organism_substance	0	5	Serum	Serum	NN	B-NP
O	6	9	and	and	CC	I-NP
B-Organism_substance	10	15	urine	urine	NN	I-NP
O	16	22	levels	level	NNS	I-NP
O	23	25	of	of	IN	B-PP
O	26	37	interleukin	interleukin	NN	B-NP
O	37	38	-	-	HYPH	O
O	38	39	8	8	CD	B-NP
O	40	42	in	in	IN	B-PP
O	43	51	patients	patient	NNS	B-NP
O	52	56	with	with	IN	B-PP
B-Cancer	57	60	non	non	AFX	B-NP
I-Cancer	60	61	-	-	HYPH	I-NP
I-Cancer	61	68	Hodgkin	Hodgkin	NN	I-NP
I-Cancer	68	69	'	'	''	I-NP
I-Cancer	69	70	s	s	JJ	I-NP
I-Cancer	71	79	lymphoma	lymphoma	NN	I-NP
O	79	80	.	.	.	O

O	81	93	Angiogenesis	Angiogenesis	NN	B-NP
O	94	99	plays	play	VBZ	B-VP
O	100	102	an	an	DT	B-NP
O	103	112	important	important	JJ	I-NP
O	113	117	role	role	NN	I-NP
O	118	120	in	in	IN	B-PP
O	121	125	many	many	JJ	B-NP
O	126	131	types	type	NNS	I-NP
O	132	134	of	of	IN	B-PP
B-Cancer	135	141	cancer	cancer	NN	B-NP
O	141	142	.	.	.	O

O	143	154	Interleukin	Interleukin	NN	B-NP
O	154	155	-	-	HYPH	I-NP
O	155	156	8	8	CD	I-NP
O	157	158	(	(	(	O
O	158	160	IL	IL	NN	B-NP
O	160	161	-	-	HYPH	B-NP
O	161	162	8	8	CD	I-NP
O	162	163	)	)	)	O
O	164	166	is	be	VBZ	B-VP
O	167	172	known	know	VBN	I-VP
O	173	175	to	to	TO	I-VP
O	176	178	be	be	VB	I-VP
O	179	180	a	a	DT	B-NP
O	181	184	pro	pro	AFX	I-NP
O	184	185	-	-	HYPH	I-NP
O	185	197	inflammatory	inflammatory	JJ	I-NP
O	198	201	and	and	CC	I-NP
O	202	205	pro	pro	AFX	I-NP
O	205	206	-	-	HYPH	I-NP
O	206	216	angiogenic	angiogenic	JJ	I-NP
O	217	225	cytokine	cytokine	NN	I-NP
O	225	226	,	,	,	O
O	227	230	and	and	CC	O
O	231	233	IL	IL	NN	B-NP
O	233	234	-	-	HYPH	O
O	234	235	8	8	CD	B-NP
O	236	239	has	have	VBZ	B-VP
O	240	244	been	be	VBN	I-VP
O	245	253	reported	report	VBN	I-VP
O	254	256	to	to	TO	I-VP
O	257	259	be	be	VB	I-VP
O	260	270	associated	associate	VBN	I-VP
O	271	275	with	with	IN	B-PP
B-Cancer	276	281	tumor	tumor	NN	B-NP
O	282	293	progression	progression	NN	I-NP
O	293	294	,	,	,	O
O	295	304	prognosis	prognosis	NN	B-NP
O	305	308	and	and	CC	I-NP
O	309	317	survival	survival	NN	I-NP
O	318	320	in	in	IN	B-PP
O	321	328	several	several	JJ	B-NP
O	329	334	types	type	NNS	I-NP
O	335	337	of	of	IN	B-PP
B-Cancer	338	345	cancers	cancer	NNS	B-NP
O	345	346	.	.	.	O

O	347	354	However	However	RB	B-ADVP
O	354	355	,	,	,	O
O	356	359	the	the	DT	B-NP
O	360	364	role	role	NN	I-NP
O	365	367	of	of	IN	B-PP
O	368	370	IL	IL	NN	B-NP
O	370	371	-	-	HYPH	B-NP
O	371	372	8	8	CD	I-NP
O	373	375	in	in	IN	B-PP
B-Cancer	376	379	non	non	AFX	B-NP
I-Cancer	379	380	-	-	HYPH	I-NP
I-Cancer	380	387	Hodgkin	Hodgkin	NN	I-NP
I-Cancer	387	388	'	'	''	I-NP
I-Cancer	388	389	s	s	JJ	I-NP
I-Cancer	390	398	lymphoma	lymphoma	NN	I-NP
O	399	400	(	(	(	O
B-Cancer	400	403	NHL	NHL	NN	B-NP
O	403	404	)	)	)	O
O	405	408	has	have	VBZ	B-VP
O	409	412	not	not	RB	I-VP
O	413	417	been	be	VBN	I-VP
O	418	423	fully	fully	RB	B-ADJP
O	424	434	determined	determine	VBN	I-ADJP
O	434	435	.	.	.	O

O	436	440	Here	Here	RB	B-ADVP
O	440	441	,	,	,	O
O	442	444	we	we	PRP	B-NP
O	445	454	evaluated	evaluate	VBD	B-VP
O	455	458	the	the	DT	B-NP
O	459	469	usefulness	usefulness	NN	I-NP
O	470	472	of	of	IN	B-PP
O	473	482	measuring	measure	VBG	B-VP
B-Organism_substance	483	488	serum	serum	NN	B-NP
O	489	492	and	and	CC	O
B-Organism_substance	493	498	urine	urine	NN	B-NP
O	499	501	IL	IL	NN	I-NP
O	501	502	-	-	HYPH	B-NP
O	502	503	8	8	CD	I-NP
O	504	510	levels	level	NNS	I-NP
O	511	513	in	in	IN	B-PP
O	514	522	patients	patient	NNS	B-NP
O	523	527	with	with	IN	B-PP
B-Cancer	528	531	NHL	NHL	NN	B-NP
O	531	532	.	.	.	O

O	533	535	We	We	PRP	B-NP
O	536	545	developed	develop	VBD	B-VP
O	546	555	reference	reference	NN	B-NP
O	556	565	intervals	interval	NNS	I-NP
O	566	569	for	for	IN	B-PP
B-Organism_substance	570	575	serum	serum	NN	B-NP
O	576	579	and	and	CC	I-NP
B-Organism_substance	580	585	urine	urine	NN	I-NP
O	586	588	IL	IL	NN	I-NP
O	588	589	-	-	HYPH	B-NP
O	589	590	8	8	CD	I-NP
O	591	596	level	level	NN	I-NP
O	597	599	in	in	IN	B-PP
O	600	603	131	131	CD	B-NP
O	604	611	control	control	NN	I-NP
O	612	623	individuals	individual	NNS	I-NP
O	623	624	.	.	.	O

O	625	627	We	We	PRP	B-NP
O	628	636	measured	measure	VBD	B-VP
B-Organism_substance	637	642	serum	serum	NN	B-NP
O	643	645	IL	IL	NN	I-NP
O	645	646	-	-	HYPH	B-NP
O	646	647	8	8	CD	I-NP
O	648	651	and	and	CC	O
B-Organism_substance	652	657	urine	urine	NN	B-NP
O	658	660	IL	IL	NN	I-NP
O	660	661	-	-	HYPH	B-NP
O	661	662	8	8	CD	I-NP
O	663	669	levels	level	NNS	I-NP
O	670	672	in	in	IN	B-PP
O	673	681	patients	patient	NNS	B-NP
O	682	686	with	with	IN	B-PP
B-Cancer	687	690	NHL	NHL	NN	B-NP
O	690	691	,	,	,	O
O	692	695	and	and	CC	O
O	696	698	we	we	PRP	B-NP
O	699	707	compared	compare	VBD	B-VP
O	708	711	the	the	DT	B-NP
O	712	726	concentrations	concentration	NNS	I-NP
O	727	731	with	with	IN	B-PP
O	732	737	those	those	DT	B-NP
O	738	740	of	of	IN	B-PP
O	741	748	control	control	NN	B-NP
O	749	760	individuals	individual	NNS	I-NP
O	760	761	.	.	.	O

O	762	765	The	The	DT	B-NP
O	766	775	reference	reference	NN	I-NP
O	776	785	intervals	interval	NNS	I-NP
O	786	789	for	for	IN	B-PP
B-Organism_substance	790	795	serum	serum	NN	B-NP
O	796	798	IL	IL	NN	I-NP
O	798	799	-	-	HYPH	B-NP
O	799	800	8	8	CD	I-NP
O	801	804	and	and	CC	O
B-Organism_substance	805	810	urine	urine	NN	B-NP
O	811	813	IL	IL	NN	I-NP
O	813	814	-	-	HYPH	B-NP
O	814	815	8	8	CD	I-NP
O	816	825	corrected	correct	VBN	B-VP
O	826	828	by	by	IN	B-PP
O	829	839	creatinine	creatinine	NN	B-NP
O	840	841	(	(	(	O
O	841	843	Cr	Cr	NN	B-NP
O	843	844	)	)	)	O
O	845	849	were	be	VBD	B-VP
O	850	852	15	15	CD	B-NP
O	852	853	.	.	.	I-NP
O	853	854	9	9	CD	I-NP
O	854	855	-	-	HYPH	I-NP
O	855	858	430	430	CD	I-NP
O	858	859	.	.	.	I-NP
O	859	860	3	3	CD	I-NP
O	861	863	pg	pg	NN	I-NP
O	863	864	/	/	SYM	B-NP
O	864	866	mL	mL	NN	I-NP
O	867	870	and	and	CC	O
O	871	872	0	0	CD	B-NP
O	872	873	.	.	.	I-NP
O	873	874	0	0	CD	I-NP
O	874	875	-	-	:	O
O	875	877	28	28	CD	B-NP
O	877	878	.	.	.	O
O	878	879	4	4	CD	B-NP
O	880	882	pg	pg	NN	I-NP
O	882	883	/	/	SYM	B-NP
O	883	885	mg	mg	NN	I-NP
O	886	888	Cr	Cr	NN	I-NP
O	888	889	,	,	,	O
O	890	902	respectively	respectively	RB	B-ADVP
O	902	903	.	.	.	O

O	904	907	The	The	DT	B-NP
O	908	922	concentrations	concentration	NNS	I-NP
O	923	925	of	of	IN	B-PP
B-Organism_substance	926	931	urine	urine	NN	B-NP
O	932	934	IL	IL	NN	I-NP
O	934	935	-	-	HYPH	B-NP
O	935	936	8	8	CD	I-NP
O	936	937	/	/	SYM	I-NP
O	937	939	Cr	Cr	NN	I-NP
O	940	944	were	be	VBD	B-VP
O	945	958	significantly	significantly	RB	B-ADJP
O	959	965	higher	high	JJR	I-ADJP
O	966	968	in	in	IN	B-PP
O	969	977	patients	patient	NNS	B-NP
O	978	982	than	than	IN	B-PP
O	983	985	in	in	IN	B-PP
O	986	994	controls	control	NNS	B-NP
O	995	996	(	(	(	O
O	996	998	48	48	CD	B-NP
O	998	999	.	.	.	O
O	999	1000	9	9	CD	B-NP
O	1000	1001	+	+	SYM	O
O	1001	1002	/	/	SYM	B-NP
O	1002	1003	-	-	SYM	B-NP
O	1003	1006	194	194	CD	B-NP
O	1006	1007	.	.	.	I-NP
O	1007	1008	4	4	CD	I-NP
O	1009	1011	vs	v	NNS	I-NP
O	1011	1012	.	.	.	O
O	1013	1014	5	5	CD	B-NP
O	1014	1015	.	.	.	I-NP
O	1015	1016	2	2	CD	I-NP
O	1016	1017	+	+	SYM	O
O	1017	1018	/	/	SYM	O
O	1018	1019	-	-	SYM	B-NP
O	1019	1021	13	13	CD	B-NP
O	1021	1022	.	.	SYM	I-NP
O	1022	1023	8	8	CD	I-NP
O	1024	1026	pg	pg	NN	I-NP
O	1026	1027	/	/	SYM	B-NP
O	1027	1029	mg	mg	NN	I-NP
O	1030	1032	Cr	Cr	NN	I-NP
O	1032	1033	,	,	,	O
O	1034	1035	P	P	NN	B-NP
O	1036	1040	less	less	JJR	B-NP
O	1041	1045	than	than	IN	I-NP
O	1046	1047	0	0	CD	I-NP
O	1047	1048	.	.	.	I-NP
O	1048	1051	001	001	CD	I-NP
O	1051	1052	)	)	)	O
O	1052	1053	.	.	.	O

O	1054	1061	However	However	RB	B-ADVP
O	1061	1062	,	,	,	O
O	1063	1068	there	there	EX	B-NP
O	1069	1073	were	be	VBD	B-VP
O	1074	1076	no	no	DT	B-NP
O	1077	1088	significant	significant	JJ	I-NP
O	1089	1100	differences	difference	NNS	I-NP
O	1101	1103	in	in	IN	B-PP
B-Organism_substance	1104	1109	serum	serum	NN	B-NP
O	1110	1112	IL	IL	NN	I-NP
O	1112	1113	-	-	HYPH	O
O	1113	1114	8	8	CD	B-NP
O	1115	1129	concentrations	concentration	NNS	I-NP
O	1130	1137	between	between	IN	B-PP
B-Cancer	1138	1141	NHL	NHL	NN	B-NP
O	1142	1150	patients	patient	NNS	I-NP
O	1151	1154	and	and	CC	O
O	1155	1163	controls	control	NNS	B-NP
O	1164	1165	(	(	(	O
O	1165	1168	159	159	CD	B-NP
O	1168	1169	.	.	.	I-NP
O	1169	1170	2	2	CD	I-NP
O	1170	1171	+	+	SYM	B-NP
O	1171	1172	/	/	SYM	I-NP
O	1172	1173	-	-	SYM	I-NP
O	1173	1175	40	40	CD	I-NP
O	1175	1176	.	.	.	I-NP
O	1176	1177	4	4	CD	I-NP
O	1178	1180	vs	v	NNS	I-NP
O	1180	1181	.	.	.	O
O	1182	1184	99	99	CD	B-NP
O	1184	1185	.	.	.	O
O	1185	1186	6	6	CD	B-NP
O	1186	1187	+	+	SYM	B-NP
O	1187	1188	/	/	SYM	I-NP
O	1188	1189	-	-	SYM	I-NP
O	1189	1192	107	107	CD	B-NP
O	1192	1193	.	.	SYM	I-NP
O	1193	1194	1	1	CD	I-NP
O	1195	1197	pg	pg	NN	I-NP
O	1197	1198	/	/	SYM	B-NP
O	1198	1200	mL	mL	NN	I-NP
O	1200	1201	;	;	:	O
O	1202	1203	P	P	NN	B-NP
O	1203	1204	=	=	SYM	B-VP
O	1204	1205	0	0	CD	B-NP
O	1205	1206	.	.	SYM	I-NP
O	1206	1209	099	099	CD	I-NP
O	1209	1210	)	)	)	O
O	1210	1211	.	.	.	O

O	1212	1220	Receiver	Receiver	NN	B-NP
O	1221	1230	operating	operate	VBG	B-VP
O	1231	1245	characteristic	characteristic	JJ	B-ADJP
O	1246	1247	(	(	(	O
O	1247	1250	ROC	ROC	NN	B-NP
O	1250	1251	)	)	)	O
O	1252	1260	analysis	analysis	NN	B-NP
O	1261	1265	gave	give	VBD	B-VP
O	1266	1267	0	0	CD	B-NP
O	1267	1268	.	.	.	O
O	1268	1270	83	83	CD	B-NP
O	1271	1274	and	and	CC	I-NP
O	1275	1276	0	0	CD	I-NP
O	1276	1277	.	.	.	O
O	1277	1279	43	43	CD	B-NP
O	1280	1283	ROC	ROC	NNP	I-NP
O	1284	1288	area	area	NN	I-NP
O	1289	1295	values	value	NNS	I-NP
O	1296	1299	for	for	IN	B-PP
B-Organism_substance	1300	1305	urine	urine	NN	B-NP
O	1306	1308	IL	IL	NN	I-NP
O	1308	1309	-	-	HYPH	B-NP
O	1309	1310	8	8	CD	I-NP
O	1310	1311	/	/	SYM	I-NP
O	1311	1313	Cr	Cr	NN	I-NP
O	1314	1317	and	and	CC	I-NP
B-Organism_substance	1318	1323	serum	serum	NN	I-NP
O	1324	1326	IL	IL	NN	I-NP
O	1326	1327	-	-	HYPH	O
O	1327	1328	8	8	CD	B-NP
O	1328	1329	,	,	,	O
O	1330	1342	respectively	respectively	RB	B-ADVP
O	1342	1343	.	.	.	O

O	1344	1349	There	There	EX	B-NP
O	1350	1353	was	be	VBD	B-VP
O	1354	1356	no	no	DT	B-NP
O	1357	1368	correlation	correlation	NN	I-NP
O	1369	1376	between	between	IN	B-PP
O	1377	1380	the	the	DT	B-NP
B-Organism_substance	1381	1386	serum	serum	NN	I-NP
O	1387	1390	and	and	CC	I-NP
B-Organism_substance	1391	1396	urine	urine	NN	I-NP
O	1397	1411	concentrations	concentration	NNS	I-NP
O	1412	1414	of	of	IN	B-PP
O	1415	1417	IL	IL	NN	B-NP
O	1417	1418	-	-	HYPH	B-NP
O	1418	1419	8	8	CD	I-NP
O	1420	1423	and	and	CC	O
O	1424	1432	clinical	clinical	JJ	B-NP
O	1433	1442	variables	variable	NNS	I-NP
O	1442	1443	,	,	,	O
O	1444	1447	the	the	DT	B-NP
O	1448	1452	only	only	JJ	I-NP
O	1453	1462	exception	exception	NN	I-NP
O	1463	1468	being	be	VBG	B-VP
O	1469	1472	the	the	DT	B-NP
O	1473	1486	international	international	JJ	I-NP
O	1487	1497	prognostic	prognostic	JJ	I-NP
O	1498	1503	index	index	NN	I-NP
O	1504	1505	(	(	(	O
O	1505	1508	IPI	IPI	NN	B-NP
O	1508	1509	)	)	)	O
O	1509	1510	,	,	,	O
O	1511	1516	which	which	WDT	B-NP
O	1517	1523	showed	show	VBD	B-VP
O	1524	1525	a	a	DT	B-NP
O	1526	1534	marginal	marginal	JJ	I-NP
O	1535	1546	correlation	correlation	NN	I-NP
O	1547	1551	with	with	IN	B-PP
B-Organism_substance	1552	1557	urine	urine	NN	B-NP
O	1558	1560	IL	IL	NN	I-NP
O	1560	1561	-	-	HYPH	B-NP
O	1561	1562	8	8	CD	I-NP
O	1562	1563	/	/	SYM	I-NP
O	1563	1565	Cr	Cr	NN	I-NP
O	1566	1572	levels	level	NNS	I-NP
O	1573	1574	(	(	(	O
O	1574	1575	P	P	NN	B-NP
O	1575	1576	=	=	SYM	B-VP
O	1576	1577	0	0	CD	B-NP
O	1577	1578	.	.	SYM	I-NP
O	1578	1580	07	07	CD	I-NP
O	1580	1581	)	)	)	O
O	1581	1582	.	.	.	O

O	1583	1587	This	This	DT	B-NP
O	1588	1593	study	study	NN	I-NP
O	1594	1603	indicated	indicate	VBD	B-VP
O	1604	1608	that	that	IN	B-SBAR
B-Organism_substance	1609	1614	urine	urine	NN	B-NP
O	1615	1617	IL	IL	NN	I-NP
O	1617	1618	-	-	HYPH	B-NP
O	1618	1619	8	8	CD	I-NP
O	1619	1620	/	/	SYM	I-NP
O	1620	1622	Cr	Cr	NN	I-NP
O	1623	1629	levels	level	NNS	I-NP
O	1630	1635	might	might	MD	B-VP
O	1636	1638	be	be	VB	I-VP
O	1639	1645	useful	useful	JJ	B-ADJP
O	1646	1648	as	as	IN	B-PP
O	1649	1650	a	a	DT	B-NP
O	1651	1661	diagnostic	diagnostic	JJ	I-NP
O	1662	1668	marker	marker	NN	I-NP
O	1669	1671	of	of	IN	B-PP
B-Cancer	1672	1675	NHL	NHL	NN	B-NP
O	1675	1676	.	.	.	O

